News Headlines

Display #
Title
Seattle to become latest U.S. city to tax sugary drinks
Pfizer receives FDA Fast Track designation for tafamidis for transthyretin cardiomyopathy
Take a coffee or tea break to protect your liver
PD Drug Performs Well in Late-Stage Study
New Study: Physicians Lack the Right Tools to Close Costly Gaps in Healthcare
WHO ranks antibiotics in a bid to counter drug resistance
PE Firms Take Out New York’s AMRI
How Much is Too Much to Pay for Newly Approved Drugs?
Call for applications: 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award
Lynparza slows advanced breast cancer progression
Loxo Oncology Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It
Investors Sigh With Relief as bluebird bio, Celgene’s CAR-T Candidate Keeps Multiple Myeloma Patients Relapse Free
Merck KGaA, F-star Alpha Strike Deal
Pfizer drug delays lung cancer growth longer than Astra’s Iressa: study
Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer
Novartis, IBM Watson Health team up
Amgen showcases a legacy of science, innovation and collaboration in Cambridge
Bacteria used as factories to produce cancer drugs
EU Approves Biogen’s Spinraza for SMA
The Best Defense is a Good Quality Offense
2-Drug HIV Treatment Filed for U.S., EU Approval
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
Philadelphia Drugmaker Iroko Pharma Pink Slips Another 122 Employees
Elated Bristol-Myers Squibb, Seattle Genetics Rewrite Agreement to Push Promising Drug Combo Into Phase III
Stock Tanks as Endocyte Cuts 40% of Workforce, Slashes 2 Clinical Programs
U.S. state, local government lawsuits over opioids face uphill battle
Pfizer defeats appeals over Zoloft birth defects
Teva’s migraine drug clears late-stage study
Ohio sues five drug companies over opioid crisis
Mylan may have overcharged U.S. for EpiPen by $1.27 billion: HHS